Homology Medicines Announces Pricing of Public Offering of Common Stock
April 07, 2021 08:52 ET
|
Homology Medicines, Inc.
BEDFORD, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, today announced the pricing of an underwritten public offering...
Homology Medicines Announces Proposed Public Offering of Common Stock
April 06, 2021 16:19 ET
|
Homology Medicines, Inc.
BEDFORD, Mass., April 06, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, today announced that the Company intends to offer and sell,...
Homology Medicines Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights
March 11, 2021 16:10 ET
|
Homology Medicines, Inc.
- Phase 2 PKU Gene Therapy Trial Recruiting Patients With Initial Data Expected by Year End - - On Track to Initiate Phase 1/2 Trials With In Vivo Gene Editing Candidate for PKU and Gene Therapy...
Homology Medicines Regains Worldwide Rights to Ophthalmology Program Based on its In Vivo Nuclease-Free Gene Editing Platform
March 01, 2021 07:30 ET
|
Homology Medicines, Inc.
- Company plans to continue advancing ophthalmic program toward a development candidate for lead indication - BEDFORD, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq:...
Homology Medicines to Participate in Upcoming Investor and Patient Advocacy Conferences
February 25, 2021 08:00 ET
|
Homology Medicines, Inc.
BEDFORD, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today presentations at the following virtual...
Homology Medicines Announces First Presentation of Data with HMI-203 In Vivo Gene Therapy Development Candidate for Hunter Syndrome
February 08, 2021 14:50 ET
|
Homology Medicines, Inc.
- IND-Enabling Studies Demonstrated Potential of a Single I.V. Administration of HMI-203 to Address Peripheral and CNS Components of Disease - - Data at WORLDSymposium™ Support Plans to Initiate a...
Homology Medicines Announces Plans for Three Clinical Programs in 2021 Spanning Phenylketonuria (PKU) and Hunter Syndrome (MPS II)
January 06, 2021 08:00 ET
|
Homology Medicines, Inc.
- Clinical Data from pheNIX Gene Therapy Phase 2 Dose Expansion Trial Expected by End of Year; Trial Currently Recruiting Patients - - Company Plans to Nominate Additional Development Candidate in...
Homology Medicines Reports Third Quarter 2020 Financial Results and Recent Highlights
November 09, 2020 16:05 ET
|
Homology Medicines, Inc.
- Based on Positive Data, Advancing pheNIX Gene Therapy Clinical Trial for PKU to Dose Expansion Phase - - $60 Million Equity Investment from Pfizer Inc. - - Unveiled In Vivo Gene Therapy Program...
Homology Medicines Announces $60 Million Equity Investment from Pfizer Inc.
November 09, 2020 08:00 ET
|
Homology Medicines, Inc.
BEDFORD, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Pfizer Inc. (NYSE: PFE) has agreed to make a $60 million...
Homology Medicines Announces Presentation of Positive Data from the Dose-Escalation Phase of the pheNIX Gene Therapy Trial for Adults with PKU
November 06, 2020 11:40 ET
|
Homology Medicines, Inc.
- Marked Reductions in Phe Observed at Two Doses - - Achieved Goal with Plans to Advance to Randomized, Concurrently Controlled Expansion Phase of Trial - - Webcast / Conference Call Today,...